[go: up one dir, main page]

CO2021009053A2 - Inhibidores de apol1 y sus métodos de uso - Google Patents

Inhibidores de apol1 y sus métodos de uso

Info

Publication number
CO2021009053A2
CO2021009053A2 CONC2021/0009053A CO2021009053A CO2021009053A2 CO 2021009053 A2 CO2021009053 A2 CO 2021009053A2 CO 2021009053 A CO2021009053 A CO 2021009053A CO 2021009053 A2 CO2021009053 A2 CO 2021009053A2
Authority
CO
Colombia
Prior art keywords
methods
apol1
inhibitors
ndkd
fsgs
Prior art date
Application number
CONC2021/0009053A
Other languages
English (en)
Inventor
Ales Medek
Yi Shi
Michael Brodney
Kevin Gagnon
Kan-Nian Hu
Peter Rose
Muna Shrestha
Faith Witkos
Jingrong Cao
Jon H Come
Leslie A Dakin
Francois Denis
Warren A Dorsch
Anne Fortier
Martine Hamel
Elaine B Krueger
Brian Ledford
Suganthini S Nanthakumar
Olivier Nicolas
Camil Sayegh
Timothy J Senter
Tiansheng Wang
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CO2021009053A2 publication Critical patent/CO2021009053A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/46—Phosphinous acids [R2POH], [R2P(= O)H]: Thiophosphinous acids including[R2PSH]; [R2P(=S)H]; Aminophosphines [R2PNH2]; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La descripción proporciona al menos una entidad seleccionada de compuestos de la fórmula (I), formas en estado sólido de ellos, composiciones que los comprenden y métodos que los usan, incluyendo el uso en el tratamiento de glomeruloesclerosis segmentaria focal (FSGS) y/o enfermedad renal no diabética (NDKD).
CONC2021/0009053A 2018-12-17 2021-07-09 Inhibidores de apol1 y sus métodos de uso CO2021009053A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862780667P 2018-12-17 2018-12-17
PCT/US2019/066746 WO2020131807A1 (en) 2018-12-17 2019-12-17 Inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
CO2021009053A2 true CO2021009053A2 (es) 2021-08-09

Family

ID=69182627

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0009053A CO2021009053A2 (es) 2018-12-17 2021-07-09 Inhibidores de apol1 y sus métodos de uso

Country Status (24)

Country Link
US (3) US11618746B2 (es)
EP (1) EP3897833A1 (es)
JP (1) JP7573528B2 (es)
KR (1) KR20210116483A (es)
CN (1) CN113453760B (es)
AR (1) AR116913A1 (es)
AU (1) AU2019405477B2 (es)
CA (1) CA3121910A1 (es)
CL (1) CL2021001561A1 (es)
CO (1) CO2021009053A2 (es)
CR (1) CR20210383A (es)
DO (1) DOP2021000116A (es)
EC (1) ECSP21052184A (es)
IL (2) IL283592B1 (es)
JO (3) JOP20210129A1 (es)
MA (1) MA54538A (es)
MX (1) MX2021007152A (es)
PE (1) PE20212302A1 (es)
SA (1) SA521422270B1 (es)
SG (1) SG11202105769XA (es)
TW (1) TWI848031B (es)
UA (1) UA128375C2 (es)
UY (1) UY38514A (es)
WO (1) WO2020131807A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
US12116343B2 (en) 2020-01-29 2024-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
TW202140459A (zh) * 2020-02-04 2021-11-01 美商維泰克斯製藥公司 Ａｐｏｌ１抑制劑之固體形式及其使用方法
KR20220151634A (ko) * 2020-03-06 2022-11-15 버텍스 파마슈티칼스 인코포레이티드 Apol-1 의존성 국소 분절성 사구체경화증을 치료하는 방법
CN116157393A (zh) 2020-06-12 2023-05-23 弗特克斯药品有限公司 Apol1的抑制剂及其用途
EP4165036A1 (en) * 2020-06-12 2023-04-19 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
AU2021286666A1 (en) * 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and use of the same
KR20230057386A (ko) * 2020-08-26 2023-04-28 버텍스 파마슈티칼스 인코포레이티드 Apol1 억제제 및 사용 방법
AU2022224648A1 (en) * 2021-02-19 2023-09-28 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
US20230119114A1 (en) * 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same
EP4440697A1 (en) * 2021-11-30 2024-10-09 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
JP2025503737A (ja) 2022-01-18 2025-02-04 メイズ セラピューティクス， インコーポレイテッド Ａｐｏｌ１阻害剤及び使用方法
JP2025505647A (ja) * 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１阻害剤としての２－メチル－４’，５’－ジヒドロピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、およびそれを使用する方法
WO2023194895A1 (en) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1
EP4573077A1 (en) * 2022-08-19 2025-06-25 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
WO2025006262A1 (en) * 2023-06-29 2025-01-02 Omniab, Inc. Tetracyclic compounds containing a fused indole for treating apol1-mediated chronic kidney disease

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
WO1998006720A1 (fr) 1996-08-09 1998-02-19 Eisai Co., Ltd. Derives de benzopiperidine
WO1999032482A1 (en) 1997-12-19 1999-07-01 Eli Lilly And Company Hypoglycemic imidazoline compounds
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
AU7514700A (en) 1999-09-07 2001-04-10 Syngenta Participations Ag Cyanopiperidines
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
CA2424222A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
AU2002360386A1 (en) 2001-11-14 2003-06-17 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of losartan potassium and process for their preparation
AU2003237593A1 (en) 2002-06-05 2003-12-22 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
ES2361924T3 (es) 2002-12-20 2011-06-24 X-Ceptor Therapeutics, Inc. Derivados de isoquinolinona y su uso como agentes terapéuticos.
CA2537349A1 (en) 2003-09-03 2005-03-10 Galapagos Nv The claimed invention relates to novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-ht2a receptor-related disorders
ES2414604T3 (es) 2004-03-03 2013-07-22 Eli Lilly And Company Moduladores del receptor nuclear de hormonas esteroides de derivados bicíclicos sustituidos con indol
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
AU2006316321A1 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
EP2086935A1 (de) 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
US20080153863A1 (en) 2006-12-22 2008-06-26 Caterina Bissantz Spiropiperidine derivatives
SI2118074T1 (sl) * 2007-02-01 2014-05-30 Resverlogix Corp. Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
EP2178870B1 (en) 2007-08-17 2018-09-19 LG Chem, Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
CA2761639C (en) 2009-05-29 2016-06-07 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
PT2501704E (pt) 2009-11-16 2013-12-05 Lilly Co Eli Compostos de espiropiperidina como antagonistas do receptor orl-1
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
WO2014085154A1 (en) 2012-11-27 2014-06-05 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
US9850203B2 (en) * 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
ES2687843T3 (es) 2014-03-27 2018-10-29 Academisch Medisch Centrum Iminoazúcares N-(5-((aril o heteroril)metiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
EP3186225A4 (en) 2014-08-27 2018-02-28 The Governing Council of the University of Toronto Cannabinoid type 1 receptor modulators
US10654838B2 (en) 2014-10-08 2020-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aminopyridine compounds useful as inhibitors of protein prenylation
MX2017006437A (es) 2014-11-21 2017-08-08 Esteve Labor Dr Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
EP3341367B1 (en) 2015-08-27 2021-02-24 Pfizer Inc Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators
CN108884096B (zh) 2016-02-08 2022-03-22 豪夫迈·罗氏有限公司 作为ddr1抑制剂的螺二氢吲哚酮
US11267780B2 (en) 2018-04-30 2022-03-08 The Trustees Of Indiana University Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease
WO2019226611A1 (en) 2018-05-22 2019-11-28 Ionis Pharmaceuticals, Inc. Modulators of apol1 expression
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
KR20220130127A (ko) 2019-12-19 2022-09-26 카스마 테라퓨틱스, 인코포레이티드 Trpml 조절제
US12116343B2 (en) 2020-01-29 2024-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
TW202140459A (zh) 2020-02-04 2021-11-01 美商維泰克斯製藥公司 Ａｐｏｌ１抑制劑之固體形式及其使用方法
KR20220151634A (ko) 2020-03-06 2022-11-15 버텍스 파마슈티칼스 인코포레이티드 Apol-1 의존성 국소 분절성 사구체경화증을 치료하는 방법
AU2021259580A1 (en) 2020-04-22 2022-11-24 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
IL297849A (en) 2020-05-07 2023-01-01 Rambam Med Tech Ltd Composition for use in the treatment of apol1-associated disease
EP4165036A1 (en) 2020-06-12 2023-04-19 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
CN116157393A (zh) 2020-06-12 2023-05-23 弗特克斯药品有限公司 Apol1的抑制剂及其用途
AU2021286666A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and use of the same
KR20230057386A (ko) 2020-08-26 2023-04-28 버텍스 파마슈티칼스 인코포레이티드 Apol1 억제제 및 사용 방법
US20230119114A1 (en) 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same
US20230203000A1 (en) 2021-11-30 2023-06-29 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4440697A1 (en) 2021-11-30 2024-10-09 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
US20250195483A1 (en) 2022-02-08 2025-06-19 Vertex Pharmaceuticals Incorporated Spiro piperidine derivatives as inhibitors of apol1 and methods of using same
CN119013281A (zh) 2022-02-08 2024-11-22 弗特克斯药品有限公司 作为apol1抑制剂的4'，5'-二氢螺[哌啶-4，7'-噻吩并[2，3-c]吡喃]衍生物和其使用方法
AU2023219516A1 (en) 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
JP2025505647A (ja) 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１阻害剤としての２－メチル－４’，５’－ジヒドロピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、およびそれを使用する方法

Also Published As

Publication number Publication date
ECSP21052184A (es) 2021-08-31
CL2021001561A1 (es) 2021-11-26
US12060346B2 (en) 2024-08-13
IL283592A (en) 2021-07-29
PE20212302A1 (es) 2021-12-10
CN113453760B (zh) 2024-05-24
KR20210116483A (ko) 2021-09-27
CR20210383A (es) 2021-09-22
CN113453760A (zh) 2021-09-28
DOP2021000116A (es) 2021-09-30
JOP20210130A1 (ar) 2023-01-30
IL319575A (en) 2025-05-01
SA521422270B1 (ar) 2024-02-18
US20230271945A1 (en) 2023-08-31
MX2021007152A (es) 2021-11-03
AU2019405477A1 (en) 2021-06-24
BR112021011564A2 (pt) 2021-08-31
IL283592B1 (en) 2025-04-01
UY38514A (es) 2020-07-31
TWI848031B (zh) 2024-07-11
US20250042878A1 (en) 2025-02-06
MA54538A (fr) 2021-10-27
TW202039471A (zh) 2020-11-01
JOP20210129A1 (ar) 2023-01-30
AU2019405477B2 (en) 2025-04-03
EP3897833A1 (en) 2021-10-27
SG11202105769XA (en) 2021-07-29
UA128375C2 (uk) 2024-06-26
US11618746B2 (en) 2023-04-04
CA3121910A1 (en) 2020-06-25
AR116913A1 (es) 2021-06-23
US20200377479A1 (en) 2020-12-03
WO2020131807A1 (en) 2020-06-25
JP7573528B2 (ja) 2024-10-25
JP2022515369A (ja) 2022-02-18
JOP20210131A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
ECSP21052184A (es) Inhibidores de apol1 y sus métodos de uso
UY38403A (es) Moduladores de la alfa-1 antitripsina
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CL2023000555A1 (es) Compuestos y métodos para el tratamiento de infecciones virales
CO2021013339A2 (es) Degradadores de stat y usos de los mismos
CO2020016285A2 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CL2023000662A1 (es) Agentes de rnai para inhibir la expresión de dux4, composiciones de los mismos y métodos de uso.
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
CR10069A (es) Anticuerpos anti-ox40l y métodos que los utilizan referencia cruzada con solicitudes relacionadas
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
ECSP21026485A (es) Piridazinonas y sus métodos de uso
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
CO2023014770A2 (es) Degradadores de cdk2 y sus usos
ECSP21026021A (es) Moduladores de la expresión de pnpla3
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
DK3962601T3 (da) 5-HT2A-agonister til anvendelse til behandling af depression
CL2022001452A1 (es) Inhibidores de masp-2 y métodos de uso.
CR20200631A (es) Modulares de la expresión de apol1
CO2022009691A2 (es) Formulaciones líquidas de tasimelteón y métodos para su uso
AR111431A1 (es) Combinaciones de fungicidas
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
UY37261A (es) Formulación combinada de tres compuestos antivirales